Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) EPS (Weighted Average and Diluted) (2016 - 2025)

Historic EPS (Weighted Average and Diluted) for Ani Pharmaceuticals (ANIP) over the last 16 years, with Q3 2025 value amounting to $1.13.

  • Ani Pharmaceuticals' EPS (Weighted Average and Diluted) rose 18897.64% to $1.13 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.63, marking a year-over-year increase of 38596.49%. This contributed to the annual value of -$1.04 for FY2024, which is 21061.42% down from last year.
  • As of Q3 2025, Ani Pharmaceuticals' EPS (Weighted Average and Diluted) stood at $1.13, which was up 18897.64% from $0.36 recorded in Q2 2025.
  • Ani Pharmaceuticals' 5-year EPS (Weighted Average and Diluted) high stood at $1.13 for Q3 2025, and its period low was -$1.93 during Q4 2021.
  • Over the past 5 years, Ani Pharmaceuticals' median EPS (Weighted Average and Diluted) value was -$0.14 (recorded in 2024), while the average stood at -$0.24.
  • Its EPS (Weighted Average and Diluted) has fluctuated over the past 5 years, first plummeted by 1894146.91% in 2022, then soared by 126666.67% in 2024.
  • Quarter analysis of 5 years shows Ani Pharmaceuticals' EPS (Weighted Average and Diluted) stood at -$1.93 in 2021, then surged by 84.98% to -$0.29 in 2022, then skyrocketed by 114.2% to $0.04 in 2023, then crashed by 1443.19% to -$0.55 in 2024, then soared by 304.36% to $1.13 in 2025.
  • Its EPS (Weighted Average and Diluted) was $1.13 in Q3 2025, compared to $0.36 in Q2 2025 and $0.69 in Q1 2025.